If you are living with HIV, one issue that may be challenging is lipodystrophy. Lipodystrophy refers to changes in body fat that include buildup or loss of fat in certain areas of the body. HARD BELLY results when the buildup of extra hard fat in the abdominal (belly) area pushes up against the abdominal wall and stretches the muscles until they become taut.
HARD BELLY fat:
*EGRIFTA SV™ is not approved to reduce the health consequences of HARD BELLY (excess visceral abdominal fat).
A number of factors may increase the risk of developing HARD BELLY, including:
HARD BELLY can be difficult for you to accurately describe and can be mistaken for general weight gain or obesity. Talk to your healthcare provider about what you’re feeling and ask them to check for HARD BELLY.
If you have trouble managing HARD BELLY on your own with exercise and a healthy diet, ask your healthcare provider about EGRIFTA SV™, which has been shown to reduce HARD BELLY in people living with HIV who have lipodystrophy.
†An approved strength of tesamorelin for injection with the same efficacy and safety of tesamorelin 1 mg/vial. The 2 mg/vial is more concentrated than the 1 mg/vial, and the recommended daily dose is 1.4 mg.
Important Information Regarding EGRIFTA SV™ (tesamorelin for injection) and COVID-19 Pandemic.
The full Prescribing Information and Important Safety Information about EGRIFTA SV™ are available here.